Innovent’s IBI343 a Monotherapy Receives the NMPA’s Breakthrough Therapy Designation for Advanced Gastric Cancer (GC)
Shots:
- The NMPA has granted BTD to IBI343 as monotx. for the treatment of advanced G/GEJ adenocarcinoma who are claudin18.2-positive and have progressed after at least 2L of prior systematic treatment
- The BTD was based on ongoing P-I trial, evaluating IBI343 monotx. in GC and continue to check efficacy & safety in the registration MRCT. Study results are expected to be published at a upcoming medical conference in 2024
- Innovent, soon to initiate registrational P-III (G-HOPE-001) MRCT of IBI343 to treat GC patients who are claudin18.2-positive, HER2-negative
Ref: Innovent | Image: Innovent
Related News:- Innovent Reports Results from the P-II Study of IBI302 for the Treatment of Neovascular Age-related Macular Degeneration (nAMD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
